03 September 2010
Keywords: Astellas, citizen petition, immunosuppressants, organ transplants
Article | 11 August 2009
Japan’s Astellas Pharma says that its North American affiliate has received notice that the US. Food and Drug Administration has substantially denied the company’s Citizen Petition, which had been submitted in September 2007, to ensure the safe and effective use of oral immunosuppressants used in organ transplant patients. In response, Astellas intends to file a complaint in US District Court in Washington DC challenging the FDA’s decision.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.